Zobrazeno 1 - 10
of 40
pro vyhledávání: '"E. A. Sokova"'
Autor:
G. I. Gorodetskaya, A. B. Prokofiev, S. Yu. Serebrova, E. Yu. Demchenkova, M. V. Zhuravleva, O. A. Demidova, T. V. Alexandrova, I. A. Mazerkina, E. A. Sokova, O. V. Muslimova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 1, Pp 105-120 (2023)
Cephalosporins are the empirical antibiotic therapy (ABT) of choice for patients with community-acquired pneumonia (CAP). When treated with antibiotics, elderly patients, especially those with comorbidities, are at higher risk of developing adverse d
Externí odkaz:
https://doaj.org/article/914e335edbe740be9a9fb6b5f7fa7c48
Autor:
O. V. Muslimova, M. V. Zhuravleva, O. A. Demidova, G. I. Gorodetskaya, A. V. Shapchenko, E. A. Sokova
Publikováno v:
Антибиотики и Химиотерапия, Vol 67, Iss 9-10, Pp 55-62 (2022)
Despite the fact that the incidence of community-acquired pneumonia (CAP) among young people is significantly lower than among older patients, the frequency of hospitalizations for severe CAP among people under 45 years of age remains high. The effec
Externí odkaz:
https://doaj.org/article/4b25a50fa332492c896fa658b2d97d54
Autor:
E. A. Sokova, V. V. Arkhipov, A. S. Kazakov, B. K. Romanov, R. N. Alyautdin, M. V. Zhuravleva
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 2, Pp 110-117 (2022)
Aztreonam is the only approved monocyclic β-lactam antibiotic for human use that is active against Gram-negative aerobes, primarily Pseudomonas аeruginosa. Aztreonam has been used for more than 35 years, and aztreonam lysine has been on the market
Externí odkaz:
https://doaj.org/article/a77fbae6300d4640a1140181d0a07218
Autor:
T. V. Alexandrova, O. V. Muslimova, M. V. Zhuravleva, A. A. Alexandrov, G. I. Gorodetskaya, E. Yu. Demchenkova, O. A. Demidova, E. A. Sokova, I. A. Mazerkina, Yu. А. Smirnova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 2, Pp 118-127 (2022)
β-lactam antibiotics, including cephalosporins, are the drugs of choice for empirical antibiotic therapy (ABT) in patients with community-acquired pneumonia. Unreasonable and irrational use of antibiotics leads to an increased risk of adverse reacti
Externí odkaz:
https://doaj.org/article/7adb171fb3c5481da6ae72200be59bbb
Autor:
O. V. Muslimova, E. A. Sokova, A. B. Prokofiev, M. V. Zhuravleva, A. V. Shapchenko, T. V. Alexandrova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 2, Pp 96-109 (2022)
Lower respiratory tract infections, which include community-acquired pneumonia (CAP), are the most common cause of death among all infectious diseases. The presence of a comorbid pathology in a patient with CAP suggests a possibility of mutual influe
Externí odkaz:
https://doaj.org/article/d1fdd43abea74605ac528723ba78b459
Autor:
O. V. Muslimova, V. A. Evteev, I. A. Mazerkina, E. A. Sokova, A. B. Prokofiev, A. V. Shapchenko, T. V. Alexandrova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 9, Iss 4, Pp 173-184 (2021)
Drug-induced kidney injury (DIKI) accounts for 8 to 60% of episodes of acute kidney injury (AKI) among hospital patients. Early DIKI detection and timely adjustment of therapy will help reduce the kidney injury incidence and mortality. The aim of the
Externí odkaz:
https://doaj.org/article/61ef441fa7c147e8b087565c53b1f2c7
Autor:
N. D. Bunyatyan, V. I. Petrov, O. V. Shatalova, A. V. Ponomareva, A. Yu. Ryazanova, V. S. Gorbatenko, A. S. Gerasimenko, E. A. Sokova
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 11, Iss 4, Pp 239-245 (2021)
Infectious process is an important cause of morbidity and mortality among patients with chronic kidney disease. Prescription of antibacterial drugs should take into account the pharmacokinetic parameters of the medicine and the individual characteris
Externí odkaz:
https://doaj.org/article/e4da436c05b849638a5480b5fb13fb30
Autor:
E. A. Sokova, V. V. Arkhipov, O. A. Demidova, I. A. Mazerkina, T. V. Alexandrova, M. V. Zhuravleva
Publikováno v:
Безопасность и риск фармакотерапии, Vol 9, Iss 3, Pp 128-135 (2021)
The frequency of adverse drug reactions (ADRs) in older patients is approximately 11.0%, according to scientific literature. Antibiotics are the third largest group (19.5%) of medicinal products in terms of ADR frequency in geriatric patients. Beta-l
Externí odkaz:
https://doaj.org/article/9750ac6f3beb42a8a058548681526d08
Publikováno v:
Безопасность и риск фармакотерапии, Vol 8, Iss 3, Pp 123-133 (2020)
About 14‒23% of all clinically used drugs have nephrotoxic potential and are a frequent cause of acute and chronic kidney problems. Acute kidney injury (AKI) is associated with a high risk of repeat hospitalisation, complications, and mortality in
Externí odkaz:
https://doaj.org/article/a0d99f5bd6ba4370a73d9c7af6e3501d
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 9, Iss 2, Pp 101-107 (2019)
This article looks into interchangeability and therapeutic equivalence of innovator and generic anticonvulsants — the first-generation and new antiepileptic drugs (AEDs). The results of a number of clinical trials assessing therapeutic equivalence
Externí odkaz:
https://doaj.org/article/864f524c5c4b4780be8f593e8b2deb4a